Magnetic Resonance Enterography and Histology in Patients With Fibrostenotic Crohn's Disease: A Multicenter Study.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 29 09 2021
accepted: 06 05 2022
entrez: 29 7 2022
pubmed: 30 7 2022
medline: 3 8 2022
Statut: ppublish

Résumé

Magnetic resonance enterography (MRE) is useful for detecting bowel strictures, whereas a number of imaging biomarkers may reflect severity of fibrosis burden in Crohn's disease (CD). This study aimed to verify the association of MRE metrics with histologic fibrosis independent of inflammation. This prospective European multicenter study performed MRE imaging on 60 patients with CD with bowel strictures before surgical resection. Locations of 61 histological samples were annotated on MRE examinations, followed by central readings using the Chiorean score and measurement of delayed gain of enhancement (DGE), magnetization transfer ratio, T2-weighted MRI sequences (T2R), apparent diffusion coefficient (ADC), and the magnetic resonance index of activity (MaRIA). Correlations of histology and MRE metrics were assessed. Least Absolute Shrinkage and Selection Operator and receiver operator characteristic (ROC) curve analyses were used to select composite MRE scores predictive of histology and to estimate their predictive value. ADC and MaRIA correlated with fibrosis (R = -0.71, P < 0.0001, and 0.59, P < 0.001) and more moderately with inflammation (R = -0.35, P < 0.01, and R = 0.53, P < 0.001). Lower or no correlations of fibrosis or inflammation were found with DGE, magnetization transfer ratio, or T2R. Least Absolute Shrinkage and Selection Operator and ROC identified a composite score of MaRIA, ADC, and DGE as a very good predictor of histologic fibrosis (ROC area under the curve = 0.910). MaRIA alone was the best predictor of histologic inflammation with excellent performance in identifying active histologic inflammation (ROC area under the curve = 0.966). MRE-based scores for histologic fibrosis and inflammation may assist in the characterization of CD stenosis and enable development of fibrosis-targeted therapies and clinical treatment of stenotic patients.

Identifiants

pubmed: 35905415
doi: 10.14309/ctg.0000000000000505
pii: 01720094-202207000-00008
pmc: PMC10476777
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00505

Informations de copyright

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Références

Am J Gastroenterol. 2007 Nov;102(11):2541-50
pubmed: 17900329
Inflamm Bowel Dis. 2015 Aug;21(8):1832-8
pubmed: 26020602
Radiology. 2018 May;287(2):494-503
pubmed: 29357272
Inflamm Bowel Dis. 2011 Aug;17(8):1759-68
pubmed: 21744431
Aliment Pharmacol Ther. 2016 Jan;43(1):61-72
pubmed: 26548868
Gastroenterology. 2020 Jan;158(1):137-150.e1
pubmed: 31476299
Abdom Imaging. 2012 Jun;37(3):387-96
pubmed: 21879316
J Crohns Colitis. 2018 May 25;12(6):718-729
pubmed: 29300851
Am J Gastroenterol. 2015 Mar;110(3):432-40
pubmed: 25623654
Eur Radiol. 2014 Mar;24(3):619-29
pubmed: 24037299
Inflamm Bowel Dis. 2011 Apr;17(4):984-93
pubmed: 20722053
Aliment Pharmacol Ther. 2015 Jan;41(2):153-66
pubmed: 25403954
Radiology. 2009 Sep;252(3):712-20
pubmed: 19635832
J Crohns Colitis. 2017 Jan;11(1):92-104
pubmed: 27364949
Gut. 2019 Jun;68(6):1115-1126
pubmed: 30944110
Gut. 2009 Aug;58(8):1113-20
pubmed: 19136510
MAGMA. 2013 Jun;26(3):291-301
pubmed: 23138635
Eur Radiol. 2020 Apr;30(4):1938-1947
pubmed: 31900705

Auteurs

Alexandre Coimbra (A)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Jordi Rimola (J)

Hospital Clinic, University of Barcelona, Barcelona, Spain.

Miriam Cuatrecasas (M)

Hospital Clinic, University of Barcelona, Barcelona, Spain.

Gert De Hertogh (G)

University Hospitals Leuven and University of Leuven, Belgium.

Gert Van Assche (G)

University Hospitals Leuven and University of Leuven, Belgium.

Ragna Vanslembrouck (R)

University Hospitals Leuven and University of Leuven, Belgium.

Henning Glerup (H)

Silkeborg Hospital, Silkeborg, Denmark; Lillebaelt Hospital, Vejle, Denmark.

Agnete Hedemann Nielsen (AH)

Silkeborg Hospital, Silkeborg, Denmark; Lillebaelt Hospital, Vejle, Denmark.

Rikke Hagemann-Madsen (R)

Silkeborg Hospital, Silkeborg, Denmark; Lillebaelt Hospital, Vejle, Denmark.

Yoram Bouhnik (Y)

Hôpital Beaujon, Paris, France.

Magaly Zappa (M)

Hôpital Beaujon, Paris, France.

Dominique Cazals-Hatem (D)

Hôpital Beaujon, Paris, France.

Geert D'Haens (G)

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Jaap Stoker (J)

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Sybren Meijer (S)

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.

Gerhard Rogler (G)

Department of Gastroenterology and Hepatology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.

Andreas Boss (A)

Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.

Achim Weber (A)

Department of Pathology and Molecular Pathology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.

Rui Zhao (R)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Mary E Keir (ME)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Alexis Scherl (A)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Alex de Crespigny (A)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Timothy T Lu (TT)

Early Clinical Development, Genentech, Inc., South San Francisco, California.

Julián Panés (J)

Hospital Clinic, University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH